Cutaneous lymphomas and COVID-19: What is known so far?
Dermatol Ther
; 34(1): e14463, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-894743
ABSTRACT
The Coronavirus disease 2019 (COVID-19) pandemic spreads quickly all over the world. There are no sufficient data in the literature about COVID-19 infection and cutaneous lymphomas. This review sheds the light on what is known so far about COVID-19 with a cutaneous lymphoma perspective. Cutaneous T-cell lymphoma (CTCL) diagnosis does not represent a predisposing factor to viral infections and most of CTCL patients have indolent disease. However, physicians should be cautious with patients with aggressive primary cutaneous lymphomas and advanced CTCL. Different treatment strategies for cutaneous lymphomas should be taken into consideration during the COVID-19 pandemic. Thus, it is highly needed to estimate the benefit-to-risk ratio on a case-by-case basis.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Lymphoma, T-Cell, Cutaneous
/
COVID-19
Type of study:
Diagnostic study
/
Etiology study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Dermatol Ther
Journal subject:
Dermatology
Year:
2021
Document Type:
Article
Affiliation country:
Dth.14463
Similar
MEDLINE
...
LILACS
LIS